BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26063163)

  • 1. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.
    Nishikii H; Kim BS; Yokoyama Y; Chen Y; Baker J; Pierini A; Alvarez M; Mavers M; Maas-Bauer K; Pan Y; Chiba S; Negrin RS
    Blood; 2016 Dec; 128(24):2846-2858. PubMed ID: 27760760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.
    Mavers M; Simonetta F; Nishikii H; Ribado JV; Maas-Bauer K; Alvarez M; Hirai T; Turkoz M; Baker J; Negrin RS
    Front Immunol; 2019; 10():1624. PubMed ID: 31379829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
    Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
    Pillai AB; George TI; Dutt S; Strober S
    Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.
    Ganguly S; Ross DB; Panoskaltsis-Mortari A; Kanakry CG; Blazar BR; Levy RB; Luznik L
    Blood; 2014 Sep; 124(13):2131-41. PubMed ID: 25139358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
    Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.
    Ma H; Lu C; Ziegler J; Liu A; Sepulveda A; Okada H; Lentzsch S; Mapara MY
    J Clin Invest; 2011 Jul; 121(7):2554-69. PubMed ID: 21670504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very Low Numbers of CD4
    Copsel S; Wolf D; Kale B; Barreras H; Lightbourn CO; Bader CS; Alperstein W; Altman NH; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1788-1794. PubMed ID: 29751114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
    Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
    Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.
    Vogtenhuber C; Bucher C; Highfill SL; Koch LK; Goren E; Panoskaltsis-Mortari A; Taylor PA; Farrar MA; Blazar BR
    Blood; 2010 Jul; 116(3):466-74. PubMed ID: 20442366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.
    Trenado A; Sudres M; Tang Q; Maury S; Charlotte F; Grégoire S; Bonyhadi M; Klatzmann D; Salomon BL; Cohen JL
    J Immunol; 2006 Jan; 176(2):1266-73. PubMed ID: 16394018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
    Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
    Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
    Zeng M; Guinet E; Nouri-Shirazi M
    Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
    Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
    J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.